Ocata Therapeutics

Ocata receives lupus nephritis grant

Wednesday, August 26, 2015

Ocata Therapeutics, a Marlborough, Mass.-based clinical stage biotechnology company, has been awarded a Small Business Innovation Research (SBIR) phase I grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to fund further preclinical development of Ocata’s proprietary Hemangio-derived Mesenchymal Cell (HMC) product for the treatment of systemic lupus erythematosus (SLE) and lupus nephritis (LN).

[Read More]